Articles On Rhythm Biosciences (ASX:RHY)

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the run following the company’s strategic update to FY22. During early morning trade, Rhythm shares are swapping hands for $1.045, up 8.8%. Rhythm moves ahead with strategic plans Inv...

The ASX finished the day in the red and the tech sector dropped more than any other sector. The ASX 200 closed at 7,062 which was 0.48 per cent down from yesterday and tech stocks shed over 3.5 per cent. The only other sector to fall over 1...

The Rhythm Biosciences Ltd (ASX: RHY) share price is a strong mover today following the release of its ColoSTAT results. Rhythm’s ColoSTAT is an experimental test-kit that is being trialled as a low-cost, easy-to-use blood test to detect c...

Summary Diagnostics company Rhythm Biosciences has confirmed that LRF enhancements have shown to improve ColoSTAT® results. Cannabis medicines developer Zelira Therapeutics has entered into a partnership with Alternative Solutions for...

Summary Medicinal cannabis player MGC Pharmaceuticals has a historic quarter with the ground-breaking achievement of listing on the LSE. Oncology company Race Oncology has an action-packed quarter with significant progress on the Three...

The Rhythm Biosciences Ltd (ASX: RHY) share price slid at market open today despite announcing a positive update in regards to its accreditation. In early morning trade, the medical device company’s shares are swapping hands for $1.09, dow...

On this day last year, global stocks capped off a historic one-month collapse with another epic fall. While no one knew at the time, that marked the COVID-19 nadir. Over the course of the following week, governments around the world said ju...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

The Rhythm Biosciences Ltd (ASX: RHY) share price has opened higher on Tuesday after the successful completion of Study 6 for its ColoSTAT product. At the time of writing, the Rhythm share price is trading at $1.60, up 6.33%. Let’s take a...

The best ASX stocks since COVID-19 have completely outperformed their peers with the top 10 up over 2000 per cent. A year since COVID-19 began life has changed for most ASX companies, but the best 10 have done particularly well. Stockhead h...

Strong performing ASX healthcare shares came few and far between in February. The S&P/ASX Health Care Index (ASX: XHJ) was down 3% for the month, compared to the 1% increase in the ASX 200.   From respiratory devices, vaccine producers...

The Rhythm Biosciences Ltd (ASX: RHY) share price is sinking today, despite announcing an additional site to its ColoSTAT clinical trial program. During the first hour of open, shares in the medical device company fell to an intraday low o...

Rhythm Biosciences (ASX:RHY) is showing it has its crap together – literally – as it works to make faecal occult ... Read More The post Rhythm keeps flying after validating prototype commercial test-kits appeared first on Stockhead.

Summary ASX-listed cancer diagnostics player Rhythm Biosciences revealed that the initial manufacturing of ColoSTAT® test kits had been completed. The diagnostics player is conducting performance and verification testing of test-kits....

It seems like Rhythm Biosciences Ltd (ASX: RHY) can do no wrong by investors at the moment. Today, the company’s shares have risen to another all-time high record following the update on the initial manufacturing of ColoSTAT. During early...

Small caps bounced back solidly from yesterday’s losses with the Small Ordinaries index finished Tuesday up 1.58 per cent to 3,123.7. The ASX 200 rose by 1.19 per cent to 6,742.6 however the Emerging Companies nano-cap index only rose by 0....

Shares in Rhythm Biosciences Ltd (ASX: RHY) are soaring higher during early afternoon trade. This comes after the company announced it has added two extra clinical trial sites for its ColoSTAT study. Rhythm’s ColoSTAT is an experimental te...

The Rhythm Biosciences Ltd (ASX: RHY) share price roared over 12% higher yesterday to close at $1.18. Over the past six-month period, the Rhythm Biosciences share price has thundered over a staggering 1,300%. Rhythm Biosciences share price...

If you to know where fund managers and investors (the famous and the unknown alike) are putting their money, we’ve ... Read More The post Trading Places: Guess how much this shareholder made out of Rhythm Biosciences in just 4 months appear...

Rhythm Biosciences leads an otherwise mildly positive two weeks for the small-cap health care sector, with 64 companies gaining ground ... Read More The post Check Up: Rhythm Biosciences shares just keep on soaring appeared first on Stockhe...

At time of writing the share price of Rhythm Biosciences Ltd [ASX:RHY] is trading at $1.37, up 5.79%. Rhythm Biosciences experienced explosive growth in its share price throughout 2020, moving up over 3,720%. The post Rhythm Biosciences Sha...

At time of writing the share price of Rhythm Biosciences Ltd [ASX:RHY] is trading at $1.37, up 5.79%. Rhythm Biosciences experienced explosive growth in its share price throughout 2020, moving up over 3,720%. The post Rhythm Biosciences Sha...

The Rhythm Biosciences Ltd (ASX: RHY) share price has continued its positive run on Tuesday. At one stage, the medical device company’s shares were up 15% to a record high of $1.30. This is almost 1,000% higher than this time last year, ma...

While most ASX companies already have products sold in the market and have built sales traction, there are also companies that are still preparing for market launch. Here I’ve listed down three ASX small cap companies that are preparing to...

The Rhythm Biosciences Ltd (ASX:RHY) share price has rocketed over 640% for the past twelve-month period. From the beginning of November alone, the share price has soared over 355%.  For the past few weeks, we’ve been watching Rhythm Biosc...

The Rhythm Biosciences Ltd (ASX: RHY) share price is climbing today after the company was granted a United States patent for ColoSTAT. At the time of writing, the Rhythm share price is up 5% to 84 cents. Rhythm develops and commercialises...

The Rhythm Biosciences Ltd (ASX: RHY) share price was an outstanding performer on Friday. At one stage, the medical device company’s shares were up 28% to a record high of 95 cents. The Rhythm Biosciences share price eventually ended the d...

Rhythm Biosciences (ASX: RHY) has appointed French company Biotem as the global manufacturer of its ColoSTAT test-kit.

Small cap ASX shares live in a world of their own. Some strike gold, some don’t. Here are some across the mining and healthcare sectors that managed to deliver significant shareholder value in November.  Best performing small cap ASX share...

Rhythm Biosciences (ASX:RHY) shares climbed again today after achieving its latest milestone – completing a prototype test kit. The company is ... Read More The post Rhythm Biosciences proves its colorectal cancer test is for real; shares u...

A few ‘Karens’ aside, Australians are largely willing to take the basic steps to avoid the coronavirus – but they ... Read More The post Dr Boreham’s Crucible: Rhythm Biosciences’ share price is passing the sniff test again appeared first o...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The health sector made a bit of progress over the last fortnight, with 64 small-cap life sciences gaining ground and just 52 losing it. Another 15 companies were flat....

A quick wrap of the ASX’s key winners and losers on Monday, September 14. Data is taken after the market closes at 4pm AEST. Stocks highlighted in yellow made potentially market-moving announcements during the day.   WINNERS Code Na...

A quick wrap of the ASX’s key winners and losers on Friday, August 14. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 902 stocks rose, 501 declined and 6...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The pundit...

A quick wrap of the ASX’s key winners and losers on Thursday, July 23. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day. Today 798 stocks rose, 500 de...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

A quick wrap of the ASX’s key winners and losers on Tuesday, July 7. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 571 stocks rose, 750 declined and 786...

Allied health group Advent Health is preparing to join the ranks of the ASX by way of a reverse takeover next month with a plan to improve efficiencies and boost profitability of its founding practices. The move entails shell company Mill...

Rhythm Biosciences (ASX:RHY) has announced the appointment of Eduardo Vom as a new non-executive director.

While the ASX falters, one small-cap is booming. The share price of Rhythm Biosciences Ltd [ASX:RHY] is up 127% at time of writing. Surging on the back of an update in regards to the company's cancer screening tech. The post Rhythm Bioscien...

Australian medical diagnostics company Rhythm Biosciences (ASX: RHY) has confirmed the antibodies in a lead biomarker of a blood test for the accurate and early detection of colorectal cancer have been successfully validated, stabilised and...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Pharmaceutical company Race Oncology (ASX: RAC) has come out of a trading halt this morning to announce $1.8 million new equity funding via a strategic placement of 6 million shares. The $0.30 per share issue price represents a 9% discount...

Gastrointestinal diseases are among the most inconvenient types of illnesses to have, and not just because they may have you running to the loo every five minutes. The field covers many diseases like Irritable Bowel Syndrome (IBS), Crohn’s...

Yesterday, Stockhead reviewed the small caps that are devising treatments to fight cancer. There are also a handful of small caps that are seeking to help with diagnostics. In other words these small caps are either seeking to identify the...

Every two weeks, Stockhead takes a look at the small cap companies that are releasing shares that have been locked away in escrow. Escrow refers to shares that are held by early investors or directors restrained from selling for a year or t...

Rhythm Biosciences (ASX: RHY) has announced the appointment of a new director and chair. The company said Otto Buttula will succeed Shane Tanner. Mr Buttula is a well-known sector...

There’s an old saying — ‘an apple a day keeps the doctor away’. But these days, its biotechs — not apples — that are working hard to keep patients out of a congested medical system. Rhythm Biosciences (ASX: RHY) main asset is Colostat – a b...

Trading Places is Stockhead’s weekly recap of substantial holder movements focusing on fund managers. Substantial shareholders are shareholders holding 5 per cent or more of a company’s shares and these can be directors, individual investor...